drugset / Trial / NCT00496340
Phase II Trial of Pentostatin and Targeted Busulfan
NaSingle-groupOpen-labelTreatment
Summary
The objective of this trial is to determine whether a regimen of pentostatin and busulfan (IV) can facilitate engraftment of human leukocyte antigen (HLA) partially compatible siblings and unrelated donor transplants by using CD4+ laboratory-guided immunosuppression among 41 transplant patients meeting the inclusion criteria.
Timeline
- Start
- 2007-07
- Primary completion
- 2013-04
- Completion
- 2013-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Busulfan | Small molecule | 200 mg/m2 | Intravenous |
| Subject | Pentostatin | Small molecule | 4 mg/m2 | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |